GR3022174T3 - Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a. - Google Patents

Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a.

Info

Publication number
GR3022174T3
GR3022174T3 GR960403615T GR960403615T GR3022174T3 GR 3022174 T3 GR3022174 T3 GR 3022174T3 GR 960403615 T GR960403615 T GR 960403615T GR 960403615 T GR960403615 T GR 960403615T GR 3022174 T3 GR3022174 T3 GR 3022174T3
Authority
GR
Greece
Prior art keywords
vaccines containing
hepatitis vaccines
monophoshoryl lipid
deacylated monophoshoryl
deacylated
Prior art date
Application number
GR960403615T
Other languages
English (en)
Inventor
Nathalie Marie- Garcon-Johnson
Pierre Hauser
Clothilde Thiriart
Pierre Voet
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3022174(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of GR3022174T3 publication Critical patent/GR3022174T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GR960403615T 1992-03-27 1996-12-30 Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a. GR3022174T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
PCT/EP1993/000712 WO1993019780A1 (en) 1992-03-27 1993-03-24 Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a

Publications (1)

Publication Number Publication Date
GR3022174T3 true GR3022174T3 (en) 1997-03-31

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960403615T GR3022174T3 (en) 1992-03-27 1996-12-30 Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a.

Country Status (28)

Country Link
EP (1) EP0633784B2 (el)
JP (1) JP3470719B2 (el)
KR (1) KR100270134B1 (el)
CN (1) CN1072963C (el)
AP (1) AP570A (el)
AT (1) ATE146678T1 (el)
AU (4) AU3751693A (el)
CA (1) CA2132833C (el)
CZ (1) CZ283424B6 (el)
DE (1) DE69306940T3 (el)
DK (1) DK0633784T4 (el)
ES (1) ES2098029T5 (el)
FI (1) FI110843B (el)
GR (1) GR3022174T3 (el)
HK (1) HK1003218A1 (el)
HU (1) HU221253B1 (el)
IL (1) IL105161A (el)
MA (1) MA22842A1 (el)
MY (1) MY111880A (el)
NO (1) NO309458B1 (el)
NZ (1) NZ249868A (el)
RU (1) RU2121849C1 (el)
SA (1) SA93130573B1 (el)
SG (1) SG48375A1 (el)
SI (1) SI9300149B (el)
SK (1) SK280160B6 (el)
UA (1) UA44688C2 (el)
WO (1) WO1993019780A1 (el)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
IL137998A0 (en) * 1998-03-09 2001-10-31 Smithkline Beecham Biolog Combined vaccine compositions
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
ES2284287T3 (es) * 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
EP2397153A1 (en) 2005-03-23 2011-12-21 GlaxoSmithKline Biologicals S.A. Novel composition
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
JP2009514841A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 粒子状アジュバントと免疫増強物質との組合せを含むインフルエンザワクチン
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
WO2007052056A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
DK3017827T3 (en) 2005-12-22 2019-02-18 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate VACCINE
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
EA015833B1 (ru) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EA200970271A1 (ru) 2006-09-11 2010-02-26 Новартис Аг Получение вакцин против вируса гриппа без использования куриных эмбрионов
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
WO2009000826A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2009001217A2 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN101971030A (zh) 2007-12-24 2011-02-09 诺华有限公司 流感吸附疫苗的试验
EP2403507B1 (en) 2009-03-05 2018-02-21 McCloskey, Jenny Colleen Treatment of infection
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
DE3886363T3 (de) * 1987-11-18 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville NANBV-Diagnostika
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0414374B1 (en) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
JP3156200B2 (ja) * 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のｈｃｖ分離株
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
WO1992011291A1 (en) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen

Also Published As

Publication number Publication date
FI944442A (fi) 1994-09-26
WO1993019780A1 (en) 1993-10-14
MY111880A (en) 2001-02-28
NO943571L (no) 1994-11-14
CZ283424B6 (cs) 1998-04-15
IL105161A (en) 1998-08-16
SA93130573B1 (ar) 2004-08-31
HK1003218A1 (en) 1998-10-16
EP0633784B2 (en) 2001-10-17
UA44688C2 (uk) 2002-03-15
NO943571D0 (no) 1994-09-26
NO309458B1 (no) 2001-02-05
KR950700757A (ko) 1995-02-20
HU9402758D0 (en) 1994-12-28
SK280160B6 (sk) 1999-09-10
AP9300502A0 (en) 1993-04-30
EP0633784B1 (en) 1996-12-27
AU3397499A (en) 1999-08-19
NZ249868A (en) 1997-03-24
IL105161A0 (en) 1993-07-08
CA2132833A1 (en) 1993-10-14
FI944442A0 (fi) 1994-09-26
JPH07505372A (ja) 1995-06-15
ES2098029T5 (es) 2002-03-16
DK0633784T3 (da) 1997-01-20
SG48375A1 (en) 1998-04-17
CN1085805A (zh) 1994-04-27
FI110843B (fi) 2003-04-15
ATE146678T1 (de) 1997-01-15
AU767755B2 (en) 2003-11-20
EP0633784A1 (en) 1995-01-18
MA22842A1 (fr) 1993-10-01
CA2132833C (en) 2007-03-06
DE69306940T3 (de) 2002-09-19
SI9300149A (en) 1993-12-31
SI9300149B (sl) 2003-02-28
DE69306940T2 (de) 1997-06-26
AU6445796A (en) 1996-11-07
KR100270134B1 (ko) 2000-10-16
DK0633784T4 (da) 2001-12-31
RU2121849C1 (ru) 1998-11-20
DE69306940D1 (de) 1997-02-06
AP570A (en) 1996-11-29
AU3751693A (en) 1993-11-08
RU94042386A (ru) 1996-08-20
CN1072963C (zh) 2001-10-17
JP3470719B2 (ja) 2003-11-25
CZ235594A3 (en) 1995-02-15
AU1000802A (en) 2002-02-21
SK115294A3 (en) 1995-06-07
HUT69931A (en) 1995-09-28
ES2098029T3 (es) 1997-04-16
HU221253B1 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
GR3022174T3 (en) Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a.
HU9202436D0 (en) Vaccines
AP9300541A0 (en) Vaccines
AP9300530A0 (en) Vaccines
AU113430S (en) A bottle
HU9500417D0 (en) Hepatitis a vaccine
AP9100332A0 (en) Vaccines
AU111329S (en) A bottle
AU112350S (en) A Bottle
AU111447S (en) A bottle
AU110494S (en) A bottle
GB9202933D0 (en) Vaccines
GB9211081D0 (en) Vaccines
GB9011358D0 (en) Vaccines
GB9006097D0 (en) Vaccines
GB9020584D0 (en) Vaccine
AU109869S (en) A bottle
AU111208S (en) A bottle
AU110114S (en) A bottle
AU109980S (en) A bottle
AU109868S (en) A bottle
AU109870S (en) A bottle
AU111823S (en) A Bottle
AU114190S (en) A bottle
AU111745S (en) A bottle